Governance & remuneration Directors Remuneration Report Performance graph and table Percentage change in remuneration of CEO The following graph sets out the performance of the company relative Base salary Benefits Annual bonus to the FTSE 100 index, and to the pharmaceutical performance CEO Sir Andrew Witty 2.5% 21 % 107% comparator group for the five year period to 31 December 2013.
UK employees 2.7% 0% 36% The graph has been prepared in accordance with the Remuneration Regulations and is not an indication of the likely vesting of awards This reflects salary earned in, benefits received in and annual bonus granted under any of the companys incentive plans.
These indices earned in respect of 2013 compared to 2012.
For the wider UK were selected for comparison purposes as they reflect both the index employee population, the salary increase includes the annual salary of which GSK is a constituent and the industry in which it operates.
review as well as any additional changes in the year, eg on promotion.
The 0% increase for benefits for UK employees reflects there being 200 no change to benefits policies or levels during the year.
It does not reflect any changes to the level of benefits an individual may have 180 received as a result of a change in role, eg promotion.
The UK population was considered to be the most relevant comparison as 160 it most closely reflects the economic environment encountered by the CEO.
140 Relative importance of pay 120 The following table sets out the percentage changes in the Groups dividends to shareholders, share buy-back and total employee pay.
GlaxoSmithKline Pharma Peers Total Return Index The 2012 dividend figure includes the supplemental dividend of FTSE 100 Total Return Index 248 million paid in 2012.
Dividends declared in respect of 2013 were 3,754 million 2012: 3,614 million, i. e. an increase of 3.9%.
This index comprises AstraZeneca, Bristol-Myers Squibb, Eli Lilly, The timing of share buy-backs is influenced by market conditions Johnson & Johnson, Merck & Co, Novartis, Pzer, Roche Holdings and Sano.
Remuneration table Total employee pay is for all Group employees globally.
2013 2012 2011 2010 2009 000 000 000 000 000 External appointments for Executive Directors CEO The Board encourages Executive Directors to hold one external Sir Andrew Witty directorship once they have become established in their role, to CEO single figure of broaden their experience and development, and help increase the remuneration 7,207 4,386 6,807 4,562 5,790 pool of candidates for Non-Executive Directors.
Any outside 1 Annual bonus award appointments are considered by the Nominations Committee to % of maximum 88% 44% 100% 59% 100% ensure they would not cause a conflict of interest and are then Vesting of LTI awards approved by the Chairman on behalf of the Board.
It is the companys 6 5 4 3 2 % of maximum 31% 24% 70% 35% 35% policy that remuneration earned from such appointments may be kept 1 2009 and 2010 bonus amounts include amounts paid under the by the individual Executive Director.
Operational Efficiency Bonus in place for those years.
The overall During 2013, Dr Moncef Slaoui received $8,000 in relation to maximum receivable was subject to a limit of 200% of base salary.
his membership of the Qatar Biomedical Research Institute Scientific 2 In respect of the 2007 PSP award.
Sir Andrew also had an Advisory Committee.
There are no other external appointments for outstanding award over 195,500 share options, granted in 2007 which he receives any remuneration.
During 2013, Sir Andrew Witty which lapsed in full.
These have not been included in the total vesting and Simon Dingemans did not hold any external appointments for percentage due to the distorting effect of aggregating conditional which they were remunerated.
3 In respect of the 2008 PSP award.
Sir Andrew also had an outstanding award over 525,000 share options, granted in 2008 which lapsed in full.
These have not been included in the total vesting percentage due to the distorting effect of aggregating conditional shares and share options.
4 In respect of the three-year element of the 2009 PSP award.
5 In respect of the four-year element of the 2009 PSP award, the three-year element of the 2010 PSP award and the 2010 DABP matching award.
6 In respect of the four-year element of the 2010 PSP award, the 2011 PSP award and the 2011 DABP matching award.
